AAM believes that all finished pharmaceuticals, pharmaceutical ingredients and active pharmaceutical ingredients (API) should be removed from the annex of products to be subject to additional duties published in USTR’s 301 Notice. Imposing an additional 25 percent tariff on such products will increase the cost of prescription drugs for patients in the United States, taxing their health and well-being, which will cause disproportionate economic harm for consumers and is unlikely to result in the desired changes to China's practices.
By Jeff Francer, SVP and General Counsel at AAM
Issues